
Superpower peptides available for pre-order. Get first access.

Not FDA-approved
Digestive & weight
KPV
Also called lysine-proline-valine (α-MSH 11-13)
Key takeaway
KPV is a three-amino-acid sequence from the tail of alpha-MSH, studied for gut and skin inflammation in cells and animals. Its evidence is preclinical, with no human efficacy trials. As of October 2026 it is still not FDA-approved, but an interim HHS policy covers conditional 503A compounding of KPV acetate in oral and topical dosage forms while rulemaking remains pending.
- Written by
- Nav SekhonResearch Lead
- Published
- October 5, 2026
- Last updated
- November 13, 2026
At a glance
| FDA status | Not FDA-approved |
| What it is | Tripeptide (3 amino acids) from the end of alpha-MSH, with anti-inflammatory activity in lab models |
| Research | Cell and animal studies; no published human studies yet |
| Compounding | HHS interim policy published October 30, 2026 covers KPV acetate in oral and topical dosage forms, subject to its conditions; not FDA approval |
| Evidence strength | Limited research |
What is KPV?
KPV is a tripeptide of lysine, proline, and valine, the last three amino acids of alpha-melanocyte-stimulating hormone (alpha-MSH), a hormone the body makes. Researchers took interest because KPV kept alpha-MSH's anti-inflammatory effect without its pigmenting action1. FDA's 2026 review treats KPV free base and KPV acetate as different active ingredients2, neither part of an FDA-approved drug, and notes websites promoting KPV as injectable, oral, topical, and nasal spray products.
Benefits of KPV under study
KPV research centers on gut and skin inflammation, in cells and animals:
- Gut: KPV lowered inflammatory signaling in human-derived intestinal and immune cells, and mice with chemically induced colitis drinking KPV-dosed water had less colitis3.
- Gut carriers: mice given KPV in coated nanoparticles inside a hydrogel had less mucosal damage and lower TNF-α4 than mice given the uncoated carrier.
- Skin: KPV restored viability and lowered IL-1β5 in dust-exposed skin cells and a 3D skin model.
- Eye: after corneal abrasion in rabbits, KPV eye drops left 8 of 8 corneas fully resurfaced6 at 60 hours, against none on saline.
What does the research show?
KPV studies each measure one step between a dose and a result:
- Cell entry: uptake through PepT13 in intestinal and immune cell lines.
- Colon delivery: an oral prodrug, proKPV, kept a fluorescent label in inflamed mouse colon at a 3.8-fold higher area under the curve7 than free labelled KPV, detectable for 24 hours.
- Disease outcome: mice with colitis given free KPV in drinking water had less inflammation8, partly independent of the MC1R receptor.
- People: FDA has identified no human exposure data by any route9, and a November 11, 2026 ClinicalTrials.gov search10 found no relevant registered KPV trial.
Side effects and safety
Human side-effect frequencies for KPV are not established. FDA's searches of its adverse-event database and medical literature retrieved no KPV reports through December 3, 20252, which does not measure how often effects occur. FDA lacks important safety information9 on KPV and flagged possible immune reactions and product-quality gaps, such as several salts sold under one name.
KPV is not named on the World Anti-Doping Agency's 2026 Prohibited List, but it falls under the list's class of non-approved substances, prohibited at all times11. Athletes subject to drug testing can face sanctions for using KPV and should check current WADA and league rules.
KPV dosage and forms
No standard KPV dose has been established, and no drug label sets one. Published amounts are animal-study quantities tied to their delivery vehicle: 100 µM3 in mouse drinking water, 16 μg/kg of KPV per day4 in the coated-nanoparticle system, and 1 mg/kg12 of intravenous free KPV. A pharmacy once nominated a 0.1% topical cream or gel2, a product strength rather than a tested dose. On donated human skin in a lab, KPV alone did not pass through detectably13. For a prescribed product, the clinician sets the amount, route, and frequency.
How does KPV work?
KPV retains much of alpha-MSH's anti-inflammatory activity, as Luger and Brzoska’s review of alpha-MSH peptides14 describes. In laboratory models it is taken up into gut and immune cells, where it is proposed to reduce pro-inflammatory signaling, including the NF-kB pathway and downstream messengers such as TNF-alpha. Some of its activity appears independent of the MC1R receptor. These are proposed mechanisms from cell and animal work; human studies would test whether the gut, skin, and eye findings carry over to people.
Is KPV FDA-approved?
No. KPV is not FDA-approved, and its compounding status changed in 2026:
- July 2026: FDA's Pharmacy Compounding Advisory Committee gave a non-binding recommendation to add KPV15 to the 503A Bulks List, the ingredients pharmacies may compound.
- October 30, 2026: HHS published an interim enforcement-discretion policy16 while that list is developed through rulemaking. Its Appendix B17 specifies KPV acetate in oral and topical dosage forms. Conditions include a patient-specific prescription, ingredients from FDA-registered manufacturers, a single active ingredient, and, for oral products, formulation-specific documentation of adequate human oral bioavailability.
The policy is not drug approval or a final decision on the Bulks List.
Where can I learn about peptides?
Superpower’s peptide library covers individual peptides the way this guide covers KPV, written and fact-checked by a team of health journalists and licensed clinicians.
The science behind peptides explains the transporters, formulations, and study designs that sit behind findings like these.